Objective: To evaluate whether headache exacerbation associated with IV dihydroergotamine (DHE) infusion predicts medium-term headache outcome in patients with chronic migraine.
Chronic migraine (CM) affects approximately 2% of adults, and can be highly disabling. 1 We previously reported our development of a 5-day inpatient course of IV dihydroergotamine (DHE) to treat chronic migraine, which built on the initial 3-day course of Raskin. 2 We reported 75% experiencing medium-term headache benefit and the importance of good nausea control. 3 We have observed that some CM patients experience transient headache worsening during DHE infusions, which may be interpreted as reason to cease the infusions and thus contribute to poorer outcomes for patients. We undertook this chart review study to assess whether transient headache worsening with DHE predicts medium-term headache outcome in patients with CM. 11 .25 mg with premedication using ondansetron or domperidone, or both. In patients with comorbid medication overuse (30%) they also had IV aspirin 4 prior to DHE. We retrospectively analyzed the prospectively collected inpatient headache diaries and contemporaneous progress notes and discharge summaries. Patients were not routinely asked if headache was exacerbated with DHE infusions, though they did keep headache diaries during the admission. We assessed a DHE worsening as headache, typically an exacerbation of the underlying phenotype, or nausea increase during or within 30 minutes of the infusion. Follow-up occurred outpatient approximately 6 weeks after discharge, at which time medium-term headache outcome was assessed by the treating clinician and recorded in the chart. Patients with opioid, barbiturate, triptan, or combination medication overuse were included.
Diagnoses of CM and medication overuse followed International Classification of Headache Disorders, 3rd edition, beta version (ICHD-III beta) criteria using documentation in the notes. 5 All patients were seen by one of us (P.J.G.).
Data analysis. The primary predictor variable was headache exacerbation with DHE infusions. While the specific dose number associated with transient headache exacerbation was not always recorded, in almost all cases it was one of the first 3 doses given. The primary outcome variable was medium-term headache benefit (any degree of benefit) at 6-week follow-up as reported by the patient in answer to the following question: Did you derive any benefit in terms of your headache from the treatment? The marginal association between headache exacerbation with DHE infusions and medium-term headache benefit, as well as associations between other predictor variables and mediumterm headache benefit, were initially assessed using frequency table methods (x 2 and Fisher exact, as appropriate) and univariate logistic regression models. Guided by the results of the marginal analyses, additional logistic models were fitted to account for the effects of potential confounding and mediating variables. To assess the potential role of nausea as a mediating influence on the effect of DHE therapy, separate models were fitted treating the former as a predictor of the latter, and including both jointly in a model for the outcome. This model also adjusted for medication overuse, leg cramping as marker of DHE binding to 5HT 1B receptors in the saphenous vein, 6 sex, and age. The results of these 2 models allowed assessment of the magnitude of the direct effect of therapy not mediated through occurrence of nausea. Model fits were screened for the presence of outliers and for lack of fit using the Hosmer-Lemeshow test. Analyses were performed using Microsoft Excel, SPSS, or Stata v. 12.0 (College Station, TX).
RESULTS
A total of 274 patients with CM underwent inpatient DHE treatment during the study period, of whom 153 were already on migraine preventives. Headache outcome information was available in 214 (78%) patients. Seven of 274 patients did not achieve their target cumulative dose of 11.25 mg, since when nausea was present, antiemetic therapy was escalated.
Those with missing outcome data did not differ in terms of age, sex, or likelihood of having nausea or medication overuse. Overall, 78% of patients with follow-up data (167/214) had medium-term headache benefit following DHE treatment. See table 1 for demographic and clinical information.
Headache exacerbation. Nineteen percent (n 5 41) had headache exacerbation with DHE infusions. Of these, 66% had medium-term headache benefit compared to 82% of those who did not have headache exacerbation (p 5 0.07). In univariate logistic regression modeling, headache exacerbation with DHE infusion was associated with reduced odds of medium-term headache benefit (odds ratio [OR] 0.43, 95% confidence interval [CI] 0.20-0.91, p 5 0.03).
However, in multivariate logistic regression analysis adjusted for nausea, leg cramping, medication overuse, sex, and age, headache exacerbation with DHE was no longer an independent predictor of medium-term headache benefit (OR 0.65) (table 2). In this model, observations from 2 individuals were excluded as outliers due to large observed influence on estimated coefficients and associated inferences. The Hosmer-Lemeshow goodness-of-fit test for the final model was consistent with an acceptable fit to the data (p 5 0.93).
Risk factors for DHE outcome. Of modifiable risk factors for headache outcome, nausea had the largest impact on the OR estimate, as the adjusted estimate for medium-term headache benefit following DHEassociated headache exacerbation changed slightly from the marginal estimate when nausea was left out of the model (OR 0.51, 95% CI 0.22-1.13, p 5 0.09), but was similar to that seen in the fully adjusted model when leg cramping (OR 0.65, 95% CI 0.28-1.51, p 5 0.31) or medication overuse (OR 0.61, 95% CI 0.26-1.40, p 5 0.24) were removed.
Nausea. Presence of nausea was significantly associated with headache exacerbation with DHE infusions (OR 11.4, 95% CI 1.51-86.15, p 5 0.02) in a model adjusting for age, sex, medication overuse, and leg cramping. Presence of nausea was an independent predictor of lower likelihood of medium-term headache benefit in the fully adjusted model (OR 0.12, 95% CI 0.02-1.00, p 5 0.05), as was the presence of The presence of transient headache exacerbation with DHE infusions has been reported previously. 3, 7 It is not unique to DHE-headache exacerbation with triptans has been reported in adults 8 and children. 9 In this study, adequate nausea control was the most important modifiable factor predicting medium-term headache benefit with DHE infusions for CM. Experimental work demonstrates a link between activation of nociceptive trigeminal pathways emesis neurons in the caudal-medial nucleus of the tractus solitarius 10 that may mediate this effect.
Younger patients with CM were found to be relatively less likely to benefit from an inpatient course of IV DHE. This age effect has also been demonstrated in acute migraine treatment wherein patients under age 34 years were less likely to benefit from triptan treatment. 11 This highlights an even greater need for nausea control in that population.
The limitations of this study include the retrospective design. It is possible some exacerbations of headache with DHE went unreported. Future studies of patients undergoing DHE treatment for CM should systematically query for this symptom. Although we reviewed patients at 6 weeks and their preventive plan was almost invariably unchanged from discharge, the preventives initiated may have been a contributor to the overall outcome. This does not itself subtract from our observation concerning the worsening phenomenon. Our patient population was a tertiary headache clinic population, though we do not think this substantively limits the generalizability of these results for all patients undergoing a course of IV DHE treatment for CM. Clinicians in all settings should focus their efforts on aggressive nausea control during a course of IV DHE for chronic migraine.
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Figure
Proportion of chronic migraine patients experiencing medium-term headache benefit from IV dihydroergotamine (DHE) treatment
Histogram represents the likelihood of medium-term headache benefit from an inpatient course of DHE by age.
